Electrolyte Correction Guidelines

Introduction to Electrolyte Imbalance Correction

The American Diabetes Association recommends that for every 1 mEq/L decrease in serum K+ below 3.5 mEq/L, the total body deficit is approximately 200-400 mEq, with a replacement strategy using potassium chloride exclusively 1
The National Kidney Foundation suggests that potassium chloride specifically corrects both hypokalemia and accompanying hypochloremic alkalosis commonly seen in patients, with an IV replacement rate of 10-20 mEq/hour via peripheral line 2
The European Society of Clinical Nutrition recommends that severe hypophosphatemia (<0.32 mmol/L or <1.0 mg/dL) causes respiratory failure, cardiac arrhythmias, and rhabdomyolysis, with IV replacement using sodium phosphate or potassium phosphate 0.08-0.16 mmol/kg IV over 6 hours 3

The American Heart Association recommends that the formula for potassium deficit calculation is K+ deficit (mEq) = (Normal K+ - Measured K+) × body weight (kg) × 0.4, with a replacement strategy using potassium chloride exclusively 1
The National Institute of Diabetes and Digestive and Kidney Diseases suggests that IV replacement rate should be maximum 10-20 mEq/hour via peripheral line, with continuous cardiac monitoring 1

The European Society of Intensive Care Medicine recommends that the formula for sodium deficit calculation is Na+ deficit (mEq) = (Target Na+ - Measured Na+) × body weight (kg) × 0.6 (males) or 0.5 (females), with a correction rate of 8-10 mEq/L in the first 24 hours 1

The American Society of Parenteral and Enteral Nutrition recommends that severe hypophosphatemia (<0.32 mmol/L or <1.0 mg/dL) causes respiratory failure, cardiac arrhythmias, and rhabdomyolysis, with IV replacement using sodium phosphate or potassium phosphate 0.08-0.16 mmol/kg IV over 6 hours 3
The National Kidney Foundation suggests that prevention in continuous renal replacement therapy (CRRT) is superior to treatment, using phosphate-containing dialysis solutions (1.0-1.2 mmol/L phosphate) to prevent depletion 3

The European Society of Cardiology recommends that severe hypomagnesemia (<0.70 mmol/L) prolongs QT interval and causes ventricular arrhythmias, with IV replacement using magnesium sulfate 1-2g (8-16 mEq) IV over 15-60 minutes for severe deficiency 3
The American Heart Association suggests that oral replacement should use organic magnesium salts (magnesium citrate, gluconate) for better bioavailability than magnesium oxide 2

The American Society of Parenteral and Enteral Nutrition recommends that in severely malnourished patients, start feeding at 10 kcal/kg/day with generous electrolyte supplementation to prevent precipitous falls in potassium, phosphate, magnesium, and calcium, with thiamine 100mg IV before feeding starts 4, 5
The National Institute of Diabetes and Digestive and Kidney Diseases suggests that generous supplementation of potassium, magnesium, phosphate, and calcium should be provided from day 1, with monitoring of electrolytes every 6-12 hours for the first 3-5 days 4, 5

The primary electrolyte abnormalities that cause flaccid quadriparesis are hyperkalemia and hypokalemia, with hyperkalemia being particularly dangerous as it can rapidly progress to cardiac arrest 6, 7, 8

Severe hyperkalemia (>6.5 mmol/L) is a life-threatening cause of flaccid quadriparesis that requires immediate recognition and treatment 6, 7, 8
Flaccid paralysis is a cardinal manifestation of severe hyperkalemia, often accompanied by paresthesias of the extremities, depressed deep tendon reflexes, and respiratory difficulties 6, 7, 8
The first clinical indicator may be ECG changes showing peaked T waves, which can progress to flattened P waves, prolonged PR interval, widened QRS complex, and ultimately sine-wave pattern leading to cardiac arrest 6, 7, 8
Hyperkalemia most commonly occurs from renal failure or release of potassium from cells 7, 8
For cardiac arrest or severe cardiotoxicity from hyperkalemia, IV calcium must be administered immediately in addition to standard ACLS care 6
The treatment sequence for hyperkalemia includes stabilizing the myocardial membrane with calcium chloride or calcium gluconate, shifting potassium into cells with sodium bicarbonate, glucose, and insulin, or nebulized albuterol, and promoting excretion with furosemide, Kayexalate, or dialysis 7, 8

Severe hypophosphatemia (<0.32 mmol/L) contributes to respiratory failure and prolonged mechanical ventilation but is less commonly a direct cause of quadriparesis compared to potassium abnormalities 9, 10, 11, 12
Hypophosphatemia occurs in 60-80% of ICU patients, particularly with intensive kidney replacement therapy and refeeding syndrome 9, 10, 11, 12
Associated with worsening respiratory failure, cardiac arrhythmias, and prolonged hospitalization 9, 10, 11, 12

Hypomagnesemia (<0.70 mmol/L) prolongs the QT interval and can lead to ventricular arrhythmias but typically does not cause isolated flaccid quadriparesis 13, 6
Occurs in up to 60-65% of critically ill patients, particularly with kidney replacement therapy using citrate anticoagulation 12
For cardiac arrest from severe hypomagnesemia, IV magnesium is recommended in addition to standard ACLS care 6

Electrolytes must be closely monitored in hospitalized patients with kidney disease receiving kidney replacement therapy, as electrolyte abnormalities occur in up to 65% of critically ill patients 9, 10, 11
Focus monitoring on phosphate, potassium, and magnesium 9, 10, 11
Use dialysis solutions containing potassium, phosphate, and magnesium to prevent electrolyte disorders during kidney replacement therapy 12